1
Participants
Start Date
November 4, 2020
Primary Completion Date
May 7, 2024
Study Completion Date
May 7, 2024
Sulfur hexafluoride lipid-type A microspheres
Injection of Sulfur hexafluoride lipid-type A microspheres (Lumason) contrast agent will be performed via the existing peripheral intravenous line using the FDA-recommended dose of 0.03 mg/kg. Two bolus injections will be performed to evaluate for dynamic bowel perfusion and several 2-minute cine clips as well as static images will be acquired during the exam.
The Children's Hospital of Philadelphia, Philadelphia
Collaborators (1)
Bracco Diagnostics, Inc
INDUSTRY
Children's Hospital of Philadelphia
OTHER